Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. France
  4. Euronext Paris
  5. Innate Pharma
  6. News
  7. Summary
    IPH   FR0010331421

INNATE PHARMA

(IPH)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Innate Pharma : to Stop Evaluating Antibody for COVID-19 After Mid-Stage Failure

07/06/2021 | 02:08am EDT


© MT Newswires 2021
All news about INNATE PHARMA
09:22aWall Street Futures in Holding Pattern Ahead of Fed Meeting Next Week
MT
08:12aTop Premarket Gainers
MT
07:52aINNATE PHARMA : Monalizumab Data from COAST Trial Presented at ESMO Congress 202..
PU
07:45aINNATE PHARMA : Monalizumab Data from COAST Trial Presented at ESMO Congress 202..
AQ
09/15GLOBAL MARKETS LIVE : Microsoft, Apple, The Boeing Company, AT&T, Activision Bli..
09/15INNATE PHARMA : REPORTS FIRST HALF 2021 FINANCIAL RESULTS AND BUSINESS UPDATE (F..
PU
09/15Innate Pharma Posts Wider H1 2021 Net Loss, Revenue Falls
MT
09/15INNATE PHARMA : Interim financial report 961.5 KB
PU
09/15INNATE PHARMA : Reports First Half 2021 Financial Results and Business Update
AQ
09/15Innate Pharma S.A. Announces Management Changes
CI
More news
Analyst Recommendations on INNATE PHARMA
More recommendations
Financials
Sales 2021 42,1 M 49,3 M 49,3 M
Net income 2021 -44,3 M -51,9 M -51,9 M
Net cash 2021 68,9 M 80,7 M 80,7 M
P/E ratio 2021 -12,3x
Yield 2021 -
Capitalization 554 M 650 M 650 M
EV / Sales 2021 11,5x
EV / Sales 2022 11,0x
Nbr of Employees 244
Free-Float 75,2%
Chart INNATE PHARMA
Duration : Period :
Innate Pharma Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends INNATE PHARMA
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 3
Last Close Price 7,00 €
Average target price 5,90 €
Spread / Average Target -15,7%
EPS Revisions
Managers and Directors
Mondher Mahjoubi Chairman-Executive Board & Chief Executive Officer
Frederic Lombard Chief Financial Officer
Hervé Eloi Dominique Brailly Chairman-Supervisory Board
Eric Vivier Chief Scientific Officer & Senior Vice President
Odile Belzunce Senior VP-Compliance, IT & Operations
Sector and Competitors
1st jan.Capi. (M$)
INNATE PHARMA36.40%440
MODERNA, INC.321.80%177 867
LONZA GROUP AG36.36%62 278
IQVIA HOLDINGS INC.43.91%49 407
CELLTRION, INC.-23.26%31 021
SEAGEN INC.-12.32%27 940